Dormant drug status can trigger generic access to an alternate Canadian Reference Product
Pharma in Brief
FEBRUARY 8, 2024
The Notice advises that if an innovative drug is categorized as “Dormant” in Health Canada’s Drug Product Database, then a generic manufacturer can compare its drug against an alternate CRP, which could include another generic drug, when filing an Abbreviated New Drug Submission ( ANDS ).
Let's personalize your content